These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 2915185)

  • 1. Plasma kinetics of complement component C4: comparison of three models.
    Wisnieski JJ; Nathanson MH
    J Lab Clin Med; 1989 Feb; 113(2):196-203. PubMed ID: 2915185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement metabolism in man: hypercatabolism of the fourth (C4) and third (C3) components in patients with renal allograft rejection and hereditary, angioedema (HAE).
    Carpenter CB; Ruddy S; Shehadeh IH; Müller-Eberhard HJ; Merrill JP; Austen KF
    J Clin Invest; 1969 Aug; 48(8):1495-505. PubMed ID: 4894302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo behavior of radioiodinated rabbit antithrombin III. Demonstration of a noncirculating vascular compartment.
    Carlson TH; Atencio AC; Simon TL
    J Clin Invest; 1984 Jul; 74(1):191-9. PubMed ID: 6376543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of endogenously labeled plasma fibronectin: incorporation into tissues.
    Deno DC; Saba TM; Lewis EP
    Am J Physiol; 1983 Oct; 245(4):R564-75. PubMed ID: 6624952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the metabolism of C4 isotypes in patients with complement activation.
    Peake PW; Pussell BA; Charlesworth JA; Gavrilovic L; Timmermans V
    Clin Exp Immunol; 1989 Oct; 78(1):49-53. PubMed ID: 2530015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo behavior of human radioiodinated antithrombin III: distribution among three physiologic pools.
    Carlson TH; Simon TL; Atencio AC
    Blood; 1985 Jul; 66(1):13-9. PubMed ID: 4005426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique C1 inhibitor dysfunction in a kindred without angioedema. I. A mutant C1 INH that inhibits C1-s but not C1-r.
    Wisnieski JJ; Knauss TC; Yike I; Dearborn DG; Narvy RL; Naff GB
    J Immunol; 1994 Mar; 152(6):3199-209. PubMed ID: 8144914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma kinetics of 125I-labelled amyloid P component in beta 2M amyloidosis: a possible approach to quantitate disease activity.
    Zingraff J; Caillat-Vigneron N; Ureña P; Gagné ER; Bererhi L; Moretti JL; Bardin T; Drüeke TB
    Nephrol Dial Transplant; 1995; 10(2):223-9. PubMed ID: 7753457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of mathematic models to assess platelet kinetics.
    Lötter MG; Heyns AD; Badenhorst PN; Wessels P; Martin van Zyl J; Kotze HF; Minnaar PC
    J Nucl Med; 1986 Jul; 27(7):1192-201. PubMed ID: 3088224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement factor C4 activation in patients with hereditary angioedema.
    Aabom A; Bygum A; Koch C
    Clin Biochem; 2017 Oct; 50(15):816-821. PubMed ID: 28412283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.
    Jager PL; Hazenberg BP; Franssen EJ; Limburg PC; van Rijswijk MH; Piers DA
    J Nucl Med; 1998 Apr; 39(4):699-706. PubMed ID: 9544684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and regulation of the fourth component of complement (C4) in the human monocytic cell line U937: comparison with that of the third component of complement (C3).
    Tsukamoto H; Nagasawa K; Yoshizawa S; Tada Y; Ueda A; Ueda Y; Niho Y
    Immunology; 1992 Apr; 75(4):565-9. PubMed ID: 1592431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the fourth component of complement (C4): assessment by rocket immunoelectrophoresis and correlation with the metabolism of C4.
    Milgrom H; Curd JG; Kaplan RA; Müller-Eberhard HJ; Vaughan JH
    J Immunol; 1980 Jun; 124(6):2780-5. PubMed ID: 7373050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kinetics of the distribution and breakdown of 1131-albumin in the rabbit. Observations on several mathematical descriptions.
    REEVE EB; ROBERTS JE
    J Gen Physiol; 1959 Nov; 43(2):415-44. PubMed ID: 14436924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three cases of factor I deficiency: the effect of treatment with plasma.
    Møller Rasmussen J; Teisner B; Jepsen HH; Svehag SE; Knudsen F; Kirstein H; Buhl M
    Clin Exp Immunol; 1988 Oct; 74(1):131-6. PubMed ID: 3219799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation in acute coronary syndromes.
    Iltumur K; Karabulut A; Toprak G; Toprak N
    APMIS; 2005 Mar; 113(3):167-74. PubMed ID: 15799759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative studies of the secretion of complement component C3 by resident, elicited and activated macrophages. Comparison with C2, C4 and lysosomal enzyme release.
    Zimmer B; Hartung HP; Scharfenberger G; Bitter-Suermann D; Hadding U
    Eur J Immunol; 1982 May; 12(5):426-30. PubMed ID: 7094993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural homologies of component C5 of human complement with components C3 and C4 by neutron scattering.
    Perkins SJ; Smith KF; Nealis AS; Lachmann PJ; Harrison RA
    Biochemistry; 1990 Feb; 29(5):175-80. PubMed ID: 2322569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catabolism and distribution of functionally heterogeneous human antithrombin III.
    Marciniak E; Romond EH
    J Lab Clin Med; 1987 Jan; 109(1):89-96. PubMed ID: 3794520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of consumption kinetics of the C4 and C2 components of complement by immune complexes "in vitro" (author's transl)].
    Roncato M; Maillet F; Peltier AP
    Pathol Biol (Paris); 1981 Feb; 29(2):95-9. PubMed ID: 7015243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.